UNSPSC 51263402: Tamsulosin

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C20H28N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G3P28OML5I, chemically known as benzenesulfonamide, 5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxy-, (r)- but generally known as tamsulosin, which bears US NIH Compound Identifier 129211. European Medicines Agency schedules Tamsulosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10827MIG.

UNSPSC 51263402 Tamsulosin is a Commodity code for a specific pharmaceutical product, but recent state and local procurement activity shows a mismatch between the code's nominal scope and what is actually being solicited. The most recent opportunities tagged to this code involve naloxone and drug deactivation systems procurement (Seminole County, Florida) and a market-intelligence request regarding direct-to-manufacturer pharmacy programs (Texas Health and Human Services Commission), neither of which relates to tamsulosin specifically. State and local buyers appear to be using this code inconsistently or the cataloging reflects administrative misalignment rather than active tamsulosin procurement demand.

Seminole County's IFB 60459723LAS, posted June 30, 2026 with a response deadline of July 26, 2023, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to the county's community health building in Sanford, Florida; vendors were required to include shipping and delivery costs, maintain drug-free workplace and E-Verify compliance, and carry workers' compensation and commercial general liability insurance. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026 to gather vendor capabilities regarding a direct-to-manufacturer prescription program that would bypass traditional pharmacy benefit managers and group purchasing organizations, signaling the state's early exploration of alternative pharmaceutical supply models. The code shows limited recent activity aligned with tamsulosin procurement, and business development professionals should verify with issuing agencies whether future opportunities will be properly recoded or whether tamsulosin demand exists under alternative UNSPSC classifications.